Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status approved; investigational
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 65044-7183; 62756-233; 38779-0191; 51552-0304; 51927-1726; 62991-1173; 39822-1055; 55500-0001; 63622-0123; 63622-0124; 63622-0125; 0469-3051; 39635-0003; 45932-0008; 55150-365
UNII 7XU7A7DROE
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3; 30652-87-0
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intestinal haemorrhage24.07.02.031; 07.12.03.005--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000141%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Neurological symptom17.02.05.010--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Cardiac valve disease02.07.02.001--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Renal injury20.01.03.015; 12.01.05.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.0380.000911%
Psychotic disorder19.03.01.002--
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.0100.000423%Not Available
Pelvic haemorrhage21.07.04.007; 12.01.09.013; 24.07.03.016--Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.000094%Not Available
Bone marrow failure01.03.03.0050.000235%
Transfusion25.06.01.003--Not Available
Treatment failure08.06.01.0170.000235%Not Available
Liver injury09.01.07.022; 12.01.17.0120.000141%Not Available
Adverse reaction08.06.01.018--Not Available
Skin mass23.07.04.014--Not Available
Anal pruritus07.03.03.002--Not Available
Anorectal discomfort07.03.03.003--Not Available
Acute kidney injury20.01.03.0160.000958%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000301%Not Available
Candida infection11.03.03.021--
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene